INTRODUCTION
Factor VIII is a plasma glycoprotein that plays an essential role in the intrinsic pathway of coagulation, as a cofactor in the proteolytic activation of Factor X by Factor IXa [1] [2] [3] . With the construction of the full-length Factor VIII cDNA and the establishment of the entire nucleotide sequence [4, 5] , the primary structure of the protein has been completely resolved. The precursor consists of 2332 amino acid residues, preceded by a signal peptide of 19 amino acid residues. It is composed of three homologous A domains, two homologous C domains and a unique B domain, arranged in the following order: A1-A2-B-A3-C1-C2 [6] (cf. Fig. 1 ). In plasma, Factor VIII circulates in complex with a carrier protein, von Willebrand Factor [7, 8] .
The structure-function relationship of Factor VIII is still largely unknown. The protein displays sequence homology with Factor V, another major cofactor in the coagulation system [1] . As a consequence of limited proteolysis, Factor VIII circulates as heterodimers of a C-terminal light chain (Mr 80000, containing domains A3, C1 and C2) and variable derivatives of the Nterminal heavy chain (Mr 50000-180000, A1 plus parts of A2 and B) [9] [10] [11] . Expression of Factor VIII activity is modulated through proteolytic cleavage by thrombin, Factor Xa and activated protein C [1, 10, [12] [13] [14] [15] . Activation by thrombin or Factor Xa involves removal of the B domain, a region that appears not to be required for activity of recombinant Factor VIII in vitro [16] [17] [18] . Fully activated Factor VIII possibly consists of the 90 kDa fragment of the heavy chain and the 80 kDa chain [9, 13] , resulting from proteolytic cleavage at Arg-740 and Arg-1648 respectively [10] . In addition, both chains contain other putatively activating cleavage sites: the 90 kDa chain at position 372 and the 80 kDa chain at 1689; cleavage at these positions results in conversion of the 90 kDa chain into fragments of 50 kDa and 43 kDa, and of the 80 kDa chain into a fragment of 73 kDa [10, 15] . Proteolytic inactivation of Factor VIII has been proposed to occur through cleavage by Factor Xa or activated protein C at Arg-336 [10] .
As an approach for the localization of functionally important domains, the mapping of epitopes of human antibodies and mouse monoclonal antibodies to Factor VIII together with studies on the inhibitory properties of these antibodies in coagulation in vitro has proven informative. Thus immunoblotting studies of plasma Factor [9, 19, 20] . A more precise location of antibody-binding sites with this method is restricted by the availability of suitable proteinase-cleavage sites on the Factor VIII protein.
In the present study we describe an epitope mapping strategy that makes use of appropriate restriction sites on the Factor VIII cDNA. This approach provided defined truncated Factor VIII fragments that could be used for immunoprecipitation studies. The epitopes of four monoclonal antibodies that were located by using this method were investigated with regard to their involvement in Factor VIII function. [21] and was found to be identical with the one published by Wood et al. [4] , except for one silent substitution of a T by a C residue at position 2976.
MATERIALS AND METHODS
Design of 'in-vitro-expression' plasmids and mRNA fragments Fig. 1 illustrates the 'in-vitro-expression' plasmids designed for this study.
pSP/FF-FL ( Fig. 1; 1 Fig. 1 ; IV). This plasmid was generated from pSP/F8-FL by deleting the 2287 bp between the HindIII site of the vector and the HindIII site of the Factor VIII cDNA at position 2277.
pSP/F8-dB925 ( Fig Immunoprecipitation of Factor VIII polypeptides synthesized in vitro was performed as follows. Translation reaction mixtures were diluted 30-fold with 10 mmTris/HCl buffer, pH 7.8, containing 150 mM-NaCl, 1O mM-EDTA, 1 % (v/v) Nonidet P40, 1 mM-phenylmethanesulphonyl fluoride, 0.02 mg of soya-bean trypsin inhibitor/ml, 10 mM-benzamidine and 5 mM-N-ethylmaleimide. Monoclonal antibodies were immobilized by attachment to Protein A-Sepharose according to the manufacturer's instructions. Preclearing, specific incubations and washing were essentially as described elsewhere [26] . After washing, the beads were boiled in 10% (w/v) SDS for 5 min and centrifuged. The supernatant was analysed by SDS/polyacrylamide-gel electrophoresis under reducing conditions by the method of Laemmli [27] , followed by autoradiography.
Monoclonal antibodies
Mouse monoclonal antibodies to human Factor VIII, namely CLB-CAg 117, CLB-CAg A, CLB-CAg 69 and CLB-CAg 9, were produced and purified as has been described previously [28] . Monoclonal antibody 1B3 was a gift from Dr. R. M. Bertina (Leiden University Hospital, Leiden, The Netherlands) and was described previously [29] . As a control, a monoclonal antibody to grass pollen (4B1, denoted here 'anti-pollen antibody') that was developed at our institute [30] coupled to CNBr-activated Sepharose-4B was added up to a ratio of 1 mg of antibody per 2000 units of Factor VIII. The total volume was adjusted to 2 litres with 50 mmTris/HCl buffer, pH 7.4, containing 250 mM-CaCl2 and 1O mM-benzamidine, and the mixture was stirred gently for 6 h at room temperature. Afterwards, the Sepharose was collected into a column (1 cm x 10 cm) at 4 'C. The column was washed with 160 ml of 10 mMTris/HCI buffer, pH 7.4, containing 2.5 mM-CaCl2 and 150 mM-NaCl and subsequently with 2 column volumes of 10 mM-Tris/HCl buffer, pH 7.4, containing 2.5 mmCaCl2 and 1.5 M-NaCl, at a flow rate of 10 ml/h. Factor VIII was eluted with a solution containing 2.5 mMCaCl2, 150 mM-NaCl, 10 mM-benzamidine, 50 % (v/v) ethylene glycol and 25 mM-lysine, pH 11. Fractions (1 ml) were collected, immediately neutralized with 10 % (v/v) of 1.5 M-imidazole, pH 7.0, and stored at -20 'C. Factor VIII purified by this method has a specific activity of 2500-3000 units/mg and a Factor VIII activity/ antigen ratio of 0.6-0.9: 1. Immunoblotting procedure Samples were subjected to SDS/7.5 %-(w/v)-polyacrylamide-gel electrophoresis under reducing conditions [27] . After electrophoresis, the separated proteins were transferred electrophoretically to nitrocellulose at 0. for 2 h at room temperature. The membrane was then washed three times with phosphate-buffered saline containing 0.1 00 (w/v) Tween 20 and incubated with I ml/lane of goat anti-(mouse IgG) antibody horseradish-peroxidase-conjugated (25 ,ug/ml) (Central Laboratory of The Netherlands Red Cross Blood Transfusion Service) in the same buffer for 2 h at room temperature. Finally, after three more washes, the immune complexes were stained with 100 ml of phosphate-buffered saline containing 0.1 mg of 4-chloro-1-naphthol/ml and 0.015 % (v/v) H202. The reaction was stopped by rinsing the membrane with water. Factor VIII assays Total protein concentration was determined by the method of Bradford [31] , with human serum albumin as standard. Factor VIII activity was determined either spectrophotometrically or in a one-stage clotting assay. The former method employs a chromogenic substrate and purified bovine coagulation factors (Coatest Factor VIII; KabiVitrum, Stockholm, Sweden) and was performed according to the manufacturer's instructions. The one-stage clotting assay was performed with congenitally Factor VIII-deficient plasma as the substrate [32] . Factor VIII antigen was measured with an e.l.i.s.a. assay based on a previously described method [33] . Factor VIII concentrations are expressed in units/ml; I unit/ml represents the concentration of Factor VIII in pooled normal human plasma. In order to evaluate various functional aspects of Factor VIII, we distinguish between the following terms. (a) Factor VIII cofactor activity is defined as the effect of Factor VIII as a cofactor of Factor IXa in the activation of Factor X. This relates to the Factor VIII activity that is measured in the spectrophotometric assay. (b) Factor VIII procoagulant activity is defined as the activity that corrects the coagulation defect of plasma of a severe haemophilia A patient in a one-stage clotting assay.
RESULTS

Immunoblotting
As a first step in the mapping of the epitopes of the monoclonal antibodies, we used immunoblotting of purified plasma Factor VIII. As is shown in Fig. 2 , this preparation consisted of multiple polypeptides with apparent molecular masses concurring with those of the Cterminal 80 kDa chain and the N-terminal 90 kDa chain plus parts of the central B domain [9, 11, 19] . The antibodies 1B3 and CLB-CAg 9 recognized all polypeptides that contain the 90 kDa fragment, whereas CLB-CAg 69 reacted with the 80 kDa chain. CLB-CAg A and CLBCAg 117, the antibody used for the Factor VIII purification, did not bind to Factor VIII under the reducing conditions in the immunoblotting experiments. However, it has previously been reported that these antibodies recognize the isolated 80 kDa chain [34] . On the basis of this preliminary localization of the antibodybinding sites we concluded that the fine mapping strategy should be focused on Fig. 3 illustrates the experimental approach for two monoclonal antibodies directed against the 80 kDa chain. Factor VIII fragments were obtained via digestion of the plasmids pSP/F8-80kl and pSP/F8-80k2 (cf. Fig. 1) at several of the restriction sites mentioned above. This resulted in C-terminally truncated forms of the 80 kDa chain, with molecular masses between 90 kDa and 18 kDa (Fig. 3, lanes 13-16) . These values correspond to the sum of the molecular masses of the respective fragments and the fused signal peptides required for appropriate sites for translation starts. In the case of the longer polypeptides smaller fragments were also observed. These probably arise as a result of incorrect starts or stops during translation, since intactness of mRNAs had been confirmed by Northern blotting (results not shown). Immunoprecipitation studies revealed that the antibody CLB-CAg 69 recognized all four 80 kDa-chainderived fragments, whereas CLB-CAg A recognized only the two longer peptides (Fig. 3, lanes 1-12) . This illustrates that our method provides a straightforward approach for detecting immunoreactive sequences. Accordingly, immunoprecipitation studies were performed with other fragments and monoclonal antibodies. The results are summarized in Fig. 4 . It appeared that the region between amino acid residues 712 and 779 is involved in the binding of both the antibody 1B3 and CLB-CAg 9. Since these antibodies are known to recognize the 90 kDa chain (Fig. 2) with Arg-740 as Cterminal residue [10] , it is concluded that the sequence from residue 713 to 740 contains at least part of the epitopes of 1B3 and CLB-CAg 9 The smallest common sequence of the peptides binding to the antibody CLBCAg 69 extends from amino acid residue 1638 to 1778. Together with the knowledge that CLB-CAg 69 recognizes the 80 kDa chain (Fig. 2) with Glu-1649 as Nterminal residue [10] , this provides evidience that the epitope of this antibody lies between residues 1648 and 1779. Fig. 4 further summarizes that CLB-CAg A recognized the polypeptides extending from amino acid residue 1562 to 2332, 2001 or 1840, but not from residue 1562 to 1778. Consequently, the epitope or part of the epitope of CLB-CAg A must be situated between amino acid residues 1778 and 1841. The third anti-(80 kDa chain) antibody included in these studies, CLB-CAg 117, displayed cross-reactivity with non-overlapping sequences. Therefore the apparently more complex epitope of this antibody could not be mapped precisely.
Inhibition studies
The antibody-binding regions that evolved from the mapping studies (Fig. 4) Plasma was incubated with an equal volume of IgG (0-100 ,ug/ml in 150 mM-NaCl/10 mM-Tris/HCl buffer, pH 7.8) for 2 h at 37 'C. Subsequently, Factor VIII activity was measured either spectrophotometrically (a) or in a clotting assay (b) as described in the Materials and methods section. The monoclonal antibodies were 1B3 (x), CLB-CAg 9 (0), CLB-CAg 69 (-) and CLBCAg A (@).
purpose the monoclonal antibodies were tested for inhibition in two distinct functional Factor VIII assays. Fig. 5 shows the results of these studies. When, upon incubation ofplasma with each of the antibodies, residual Factor VIII was determined spectrophotometrically (Fig.  Sa) , CLB-CAg A appeared to be an effective inhibitor of Factor VIII cofactor activity. However, CLB-CAg 69, 1B3 and CLB-CAg 9 did not inhibit Factor VIII up to the highest concentration tested (100 ,ug/ml), suggesting that these antibodies are non-inhibitory. Interestingly, this is in marked contrast with the results obtained when residual Factor VIII activity was quantified by use of the clotting assay (Fig. 5b) . CLB-CAg 69 was found to be a weak inhibitor of Factor VIII procoagulant activity. Both 1B3 and CLB-CAg 9 appeared to inhibit Factor VIII up to about 50 %. At antibody concentrations exceeding 5 ,ug/ml inhibition was no longer dosedependent, indicating that Factor VIII was saturated with antibody. It was concluded that inhibition of Factor VIII procoagulant activity is not necessarily identical with inhibition of Factor VIII cofactor function.
DISCUSSION
The mapping of epitopes of both inhibitory and noninhibitory antibodies has proven a valuable tool in studying the structure-function relationship of coagulation Factor VIII. Most studies reported so far [9, 13, 19, 20, 35] have been performed with purified plasma Factor VIII and fragments obtained by thrombin digestion. This approach, however, is restricted by the location of the specific sites susceptible to limited proteolysis. In the present study we used a mapping strategy based on the selection of appropriate restriction sites on the Factor VIII cDNA. Factor VIII 'in-vitro-expression' plasmids were derived from pSP64, a vector containing the bacteriophage SP6 promoter that allows specific '.run-off' transcription of inserted cDNA sequences [22] . This permits the synthesis of precisely defined radiolabelled Factor VIII fragments that can be used directly in immunoprecipitation studies (Figs. 3 and 4) . This method provides multiple protein fragments from a limited number of template-containing plasmids. As such, it has some technical advantages over techniques requiring the construction of separate expression plasmids for each individual fragment [36] . Similar strategies have been applied successfully to the mouse transformation-associated protein p53 [37] and the rat glycocorticoid receptor [38] . This approach avoids the need for sequencing multiple randomly generated cDNA fragments encoding immunoreactive polypeptides, as is required when employing a recombinant DNA epitope library [39, 40] . The method is particularly relevant to linear epitopes not containing post-translational modifications. Fig. 6 summarizes the results of the mapping studies of four monoclonal antibodies to Factor VIII. Two antibodies (CLB-CAg 9 and 1B3) were both directed against the C-terminal region of 28 amino acid residues of the 90 kDa chain. Of two antibodies (CLB-CAg A and CLBCAg 69) recognizing the 80 kDa chain of 684 amino acid residues the epitope-containing regions were confined to sequences spanning 62 and 130 amino acid residues respectively. A more precise localization may be obtained by further truncation of the Factor VIII cDNA within the regions encoding these amino acid sequences.
Alternatively, the present data may serve as a basis for an approach utilizing synthetic peptides. For instance, the epitope of the antibody CLB-CAg 69 was mapped in more detail on a peptide extending from Lys-1673 to Arg-1689 [41] . Our studies on the localization of the epitopes of CLB-CAg A and 1 B3 extend previous observations that these antibodies recognize the 80 kDa chain and 90 kDa chain respectively [34] . On the other hand, 1B3 has previously been suggested to bind the 80 kDa chain on the basis of-monoclonal-antibody cross-reactivity studies [42] . However, we were not able to confirm this using our direct mapping technique.
In order to establish the involvement of the antibodybinding regions in Factor VIII function, the inhibitory characteristics of the antibodies were studied. Until now, such studies have been limited to one-stage clotting assays [9, 19, 20, 43] . In the present study we also characterized the inhibitory properties of anti-(Factor VIII) antibodies at the level of Factor Xa formation, which is the Factor-VIII-dependent step in the coagulation cascade. This dual approach revealed differences that may have major implications for the interpretation of functional studies with monoclonal antibodies as inhibitory probes: whereas all four antibodies studied were inhibitory in the clotting assay, three of them were non-inhibitory in the spectrophotometric assay (see Fig.  5 ). This finding suggests that these antibodies interfere in a process that is rate-limiting in clot formation, but not in Factor Xa generation. Previous studies have shown that Factor VIII supports Factor Xa generation only after a short lag period, during which feedback activation of Factor VIII by Factor Xa or thrombin takes place [44, 45] . Studies on Factor X activation in plasma have demonstrated that coagulation already occurs as an early event, within the lag period, in Factor Xa formation [45] [46] [47] [48] . Accordingly, the activation of Factor VIII that precedes the Factor VIIIa-dependent Factor Xa generation has been suggested to be rate-limiting for coagulation in vitro, without affecting the final extent of Factor Xa generated [45] . Therefore the inhibition by the three monoclonal antibodies in the clotting assay may be explained by interference in Factor VIII activation rather than inhibition of Factor VIII cofactor activity itself. This explanation would be in agreement with an earlier proposal concerning the antibody 1B3 [29] . Our suggestion for the inhibition mechanism is supported by the location of the epitopes of the antibodies displaying this inhibitory effect (Fig. 6 ): all three antibodies are directed against sequences in the close proximity of cleavage sites involved in the proteolytic activation of Factor VIII [10, 15] . Several other investigators have described monoclonal antibodies directed against epitopes close to thrombincleavage or Factor Xa-cleavage sites, both on the Cterminal region of the 90 kDa chain [9, 49] and on the Nterminal region of the 80 kDa chain [19, 50] . Although these antibodies do inhibit Factor VIII procoagulant activity, no data are available from inhibition studies on the level of Factor X activation. Therefore it is uncertain whether, as in our studies, Factor Xa generation is unaffected by these antibodies. For structure-function studies based on the epitope mapping of 'inhibitory' antibodies, it should be established, whether the antibodies in question actually inhibit Factor VIII cofactor function. Antibodies of this type, such as CLB-CAg A, may be the subject of further studies on the assembly of the Factor X-activating complex. The antibodies binding in the vicinity of cleavage sites may prove of interest for studies on the proteolytic activation of Factor VIII. With regard to the physiological relevance of such studies, it may be noted that the antibody CLB-CAg 69 binds to a sequence that is involved in the high-affinity interaction of Factor VIII with von Willebrand Factor [41] . The 
